Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Immunome (IMNM)
NASDAQ:IMNM
Holding IMNM?
Track your performance easily
IMNM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$8.97 - $30.96
Previous CloseN/A
Volume79.27K
Average Volume (3M)796.62K
Market Cap
$615.43M
Enterprise Value$642.79M
Total Cash (Recent Filing)$1.60M
Total Debt (Recent Filing)$564.00K
Price to Earnings (P/E)―
Beta1.62
Next Earnings
Mar 26, 2025EPS Estimate
-0.67Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.12
Shares Outstanding62,416,843
10 Day Avg. Volume668,675
30 Day Avg. Volume796,617
Standard Deviation0.41
R-Squared0.05
Alpha0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)62.30
Price to Cash Flow (P/CF)-4.60
P/FCF Ratio0.00
Enterprise Value/Market Cap1.04
Enterprise Value/Revenue63.46
Enterprise Value/Gross Profit45.85
Enterprise Value/Ebitda-3.16
Forecast
1Y Price Target
$26.75Price Target Upside171.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Immunome News
PremiumCompany Announcements
Immunome, Inc. Reports Q3 2024 Financial Results
Options Prices
Currently, No data available
---
Ownership Overview
1.73% Insiders
22.97% Mutual Funds
39.22% Other Institutional Investors
25.44% Public Companies and Individual Investors
IMNM FAQ
What was Immunome’s price range in the past 12 months?
Immunome lowest stock price was $8.97 and its highest was $30.96 in the past 12 months.
What is Immunome’s market cap?
Immunome’s market cap is $615.43M.
When is Immunome’s upcoming earnings report date?
Immunome’s upcoming earnings report date is Mar 26, 2025 which is in 67 days.
How were Immunome’s earnings last quarter?
Immunome released its earnings results on Nov 13, 2024. The company reported -$0.78 earnings per share for the quarter, missing the consensus estimate of -$0.551 by -$0.229.
Is Immunome overvalued?
According to Wall Street analysts Immunome’s price is currently Undervalued.
Does Immunome pay dividends?
Immunome does not currently pay dividends.
What is Immunome’s EPS estimate?
Immunome’s EPS estimate is -0.67.
How many shares outstanding does Immunome have?
Immunome has 62,416,843 shares outstanding.
What happened to Immunome’s price movement after its last earnings report?
Immunome reported an EPS of -$0.78 in its last earnings report, missing expectations of -$0.551. Following the earnings report the stock price went down -3.883%.
Which hedge fund is a major shareholder of Immunome?
Currently, no hedge funds are holding shares in IMNM
---
Immunome Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$26.75 (171.30% Upside)
$26.75 (171.30% Upside)
Blogger Sentiment
Bullish
IMNM Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 13.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.8%
Last 30 Days ▲ 4.6%
Last 30 Days ▲ 4.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.21%
12-Months-Change
Fundamentals
Return on Equity
-276.36%
Trailing 12-Months
Asset Growth
175.76%
Trailing 12-Months
Company Description
Immunome
Immunome Inc is a biopharmaceutical company engaged in the discovery and development of novel antibody-based drugs. The company's proprietary discovery platform identifies novel therapeutic antibodies and their targets by leveraging highly educated components of the immune system, memory B cells, from patients who have learned to fight off their disease. It is developing treatments for treating cancer and other infectious diseases.
---
IMNM Stock 12 Month Forecast
Average Price Target
$26.75
▲(171.30% Upside)
Technical Analysis
ADC Therapeutics
―
AlloVir
―
Corvus Pharmaceuticals
―
Kala Pharmaceuticals
―
Vir Biotechnology
―
Inovio Pharmaceuticals
―
Best Analysts Covering IMNM
1 Year
1 Year Success Rate
1/9 ratings generated profit
1 Year Average Return
-25.46%
reiterated a buy rating 2 months ago
Copying David Nierengarten's trades and holding each position for 1 Year would result in 11.11% of your transactions generating a profit, with an average return of -25.46% per trade.
---